Grants and Contributions:
Title:
Preclinical Efficacy of Gene Therapy in Brain and Ocular Applications
Agreement Number:
974365
Agreement Value:
$252,000.00
Agreement Date:
May 1, 2021 - Mar 18, 2022
Description:
The proposed project will involve repeat dose testing in a Huntington's Disease model to demonstrate the ability to perform titratable genome editing. Additionally the project will involve proof of concept testing in other organ models of genetic disease.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6S 1Z3
Reference Number:
172-2021-2022-Q2-974365
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
758555288
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 252,000 dollars.
Amendment Date
Sep 29, 2021
Recipient's Legal Name:
Incisive Genetics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: